FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma <br>
FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Share FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

Sign up to save your podcasts

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma